Last updated: April 25, 2026
In re: Seroquel XR Antitrust Litigation (1:20-cv-01076): Litigation Status, Claims, Theories, and Exposure
What is the case and who brought it?
The litigation is In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, filed as 1:20-cv-01076. The caption indicates it is a quasi class action / consolidated antitrust proceeding focused on extended-release quetiapine fumarate marketed as Seroquel XR. The procedural posture and substantive framing are consistent with pharmaceutical “brand-generic” or “product-hopping” related antitrust theories used in price-fixing and reverse-payment cases, but the precise factual allegations, named defendants, and specific asserted antitrust counts must be confirmed from the docket and operative complaints.
What antitrust claims are typically asserted in Seroquel XR pricing cases?
In practice, Seroquel XR antitrust filings in federal court have paired competition-law theories with allegations tied to patent thickets, exclusionary conduct, and market power. Commonly asserted claim types in these matters include:
- Section 1 of the Sherman Act (agreement-based exclusion or restraints of trade)
- Section 2 of the Sherman Act (monopolization or attempted monopolization)
- Illinois Brick / indirect purchaser rules adapted to the named plaintiffs’ purchaser class theory
- State law analogs where applicable (often consumer-fraud and antitrust statutes tied to Sherman Act theories)
This litigation’s exact pleaded counts and elements depend on the operative consolidated complaint and any amended pleadings.
What litigation documents control the merits and exposure?
Merits exposure in antitrust pharmaceutical cases is driven by:
- The operative consolidated complaint (theory, parties, product market definition, timeline of alleged conduct, and damages model)
- Motion-to-dismiss decisions (which allegations survive and which are dismissed)
- Class certification rulings (if a class is certified, the scope of injunctive or damages exposure changes materially)
- Summary judgment or trial orders (if reached)
- Settlement agreements and dismissal orders (often with classwide releases)
For a complete, accurate litigation analysis, the controlling items are the docket entries tied to: (i) complaint amendments; (ii) motions to dismiss; (iii) class certification; (iv) scheduling orders; and (v) any settlement or final judgment.
What is the procedural posture (status) of 1:20-cv-01076?
A complete status assessment requires the latest docket state: pending motions, whether the case is stayed, whether defendants have been dismissed, and whether a settlement has been entered. Without the docket timeline and last-filed entries, a status statement would risk being inaccurate.
What is the core litigation theory of harm in “Seroquel XR” antitrust cases?
Antitrust cases targeting branded antipsychotic extended-release drugs generally allege one or more of the following mechanisms:
- Exclusionary conduct delaying generic entry through settlement agreements or litigation conduct
- Agreements restricting market competition (e.g., coordination to prevent, delay, or limit generic substitution)
- Supply or distribution arrangements maintaining brand exclusivity beyond lawful patent expiration
- Fraud on the patent office / sham litigation (when pleaded) to extend effective exclusivity
The precise “what happened” narrative for this specific docket is determined by the operative complaint’s allegations and documentary exhibits.
How do courts typically evaluate pharmaceutical antitrust pleadings?
For Sherman Act claims in pharmaceutical settings, courts frequently scrutinize:
- Market definition (product and geographic market)
- Exclusion vs. delay characterization (whether the conduct plausibly caused anticompetitive effects)
- Agreement plausibility for Section 1 claims (direct or circumstantial evidence standard at pleading)
- Monopoly power and relevant timeframe for Section 2 claims
- Causation and damages methodology (especially for indirect purchasers and multi-product prescribing)
Dismissal risk increases where the complaint relies on conclusory allegations without binding evidence or robust causal allegations.
What damages exposure is typically at issue?
Damages frameworks in brand drug antitrust matters usually hinge on:
- Overcharge quantification from delayed generic entry
- But-for generic entry scenarios
- Substitution rates and prescribing dynamics
- Pass-through assumptions for indirect purchaser plaintiffs
- Apportionment across multiple strengths and formulations
- Statute-of-limitations windows
Whether this case targets single formulation Seroquel XR or a broader class of extended-release quetiapine products affects the damages model.
What are the key issues for class certification?
Class certification in consumer and purchaser antitrust cases often turns on:
- Common proof of anticompetitive impact
- Reliance/transaction causation standards based on the plaintiff category
- Manageability of damages models
- Variability in prescribing and payer behavior
- Whether the class is limited to branded purchaser channels (e.g., direct payors vs. pharmacy channel)
If the case is structured as an indirect purchaser class, Illinois Brick and state-by-state antitrust statutes drive how damages and injury are proven.
What settlement dynamics are typical in these cases?
Where antitrust pharmaceutical claims are tied to delayed entry, settlements often include:
- Classwide releases covering covered claims and time periods
- Allocation mechanisms across claimant categories
- Non-admission provisions
- Court-approval findings for fairness and adequacy
Settlement affects final exposure by converting uncertain merits risk into defined payment and release scope.
What can be stated with certainty from the provided information?
Only the following is confirmed from the prompt:
- Case name: In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation
- Docket number: 1:20-cv-01076
A litigation summary and analysis that names:
- the court and judge
- defendants
- the operative complaint date
- the dismissal / class certification outcomes
- the latest docket status
- the settlement terms
- and the specific legal theories and counts surviving
requires a factual record from the docket and operative pleadings. Without that record, a complete and accurate analysis cannot be produced.
Key Takeaways
- The matter is In re: Seroquel XR Antitrust Litigation, docketed as 1:20-cv-01076.
- A defensible litigation analysis requires operative pleadings, docket orders, and rulings; these are not provided in the prompt.
- Without docket-specific facts, any claim-counts, outcomes, or exposure estimates would be speculative.
FAQs
1) What is the docket number for the Seroquel XR antitrust case?
It is 1:20-cv-01076.
2) What drug and formulation is the case about?
Extended-release quetiapine fumarate, marketed as Seroquel XR.
3) Is this case an individual lawsuit or consolidated litigation?
It is styled as In re antitrust litigation, indicating consolidated/centralized management.
4) What legal theories are typically litigated in branded antipsychotic antitrust cases?
Courts commonly see Sherman Act Section 1 and Section 2 theories tied to delayed entry, exclusion, and alleged anticompetitive conduct, with damages based on overcharges and substitution dynamics.
5) What determines final exposure in these cases?
The operative complaint’s surviving claims, class certification findings, and any settlement or dispositive rulings.
References
No sources were provided in the prompt, and no verifiable docket/pleading text is included.
